Condition: Diffuse Cutaneous Systemic Sclerosis · Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
This study is a prospective, open-label, randomized, controlled, multi-center clinical trial. The aim of this study is to investigate the efficacy and safety of Telitacicept in adults with early diffuse cutaneous systemic sclerosis (dcSSc), with Mycophenolate Mofetil (MMF) administered as a background treatment.
This description comes directly from the study's public registry record.
JING XUE, PhD · 86-13858121751 · jingxue@zju.edu.cn
Always discuss trial participation with your own doctor first.
| Affiliated Hospital of Yangzhou University | Yangzhou, Jiangsu, China | Recruiting |
| Huashan Hospital of Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
| Hangzhou First People's Hospital | Hangzhou, Zhejiang, China | Recruiting |
| Sir Run Run Shaw Hospital, Zhejiang University School Of Medicine | Hangzhou, Zhejiang, China | Recruiting |
| The Second Affiliated Hospital of Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
| Changxing People's Hospital | Huzhou, Zhejiang, China | Recruiting |
| The First Hospital of Jiaxing | Jiaxing, Zhejiang, China | Recruiting |
| Ningbo First Hospital | Ningbo, Zhejiang, China | Recruiting |
| The First Affiliated Hospital of Wenzhou Medical University | Wenzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06375005